JPRN-jRCT2080220282未知2 期
A dose-finding study for SPM 962 in advanced Parkinson's disease patients with L-dopa adjunct therapy
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1. Subject diagnosed as having Parkinson's disease in accordance with Diagnostic Criteria established by the Research Committee of MHW-specified Intractable Neurodegenerative Diseases (1995)
- •2. Aged over 30 years and less than 80 years at the time of informed consent
- •3. Hoehn & Yahr stage II - IV (on time)
- •4. Total UPDRS Part III score is over 10 at screening test (on time)
- •5. Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962
- •6. Subject has any of the following problematic symptoms
- •1) Wearing off phenomenon
- •2) On and off phenomenon
- •3) Delayed-on and/or No-on phenomenon
- •4) Not well controlled with L-dopa due to adverse effect
- •5) Weakening of L-dopa efficacy
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsParkinson's DiseaseNCT01628848Otsuka Pharmaceutical Co., Ltd.174
进行中（未招募）
1 期
A Single and Multiple Dose Study of DSP-9632PJPRN-jRCT2071210088akamura Hiroki80
已完成
2 期
A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsParkinson's DiseaseNCT01634243Otsuka Pharmaceutical Co., Ltd.64
已完成
不适用
Dose-Finding Study and Assessment of Safety of a Supplement Containing Mushroom Extract for Reducing LDL-C, T-Chom, and Body Fat/A (healthy adults or adults with obese tendencies)JPRN-UMIN000019670TES Holdings Co., Ltd.80
已完成
1 期
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)NeoplasmsMalignantNCT00880568Merck Sharp & Dohme LLC27